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SUMMARY
Proteolytic joint destruction in inflammatory and non-inflammatory arthropathy is believed to be mediated, at least in part, by 
the plasminogen activation (PA) system. To further investigate possible involvement of the PA system, we qiu 
immunoreactive urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA), both plasminogen 
activator inhibitors (PAI-1 and PAI-2) and u-PA-receptor (u-PAR) in synovial tissue extracts of 14 patients with rheumatoid 
arthritis (RA) and 12 with osteoarthritis (OA). u-PA, PAI-1, PAI-2 and u-PAR concentrations were significantly higher in RA
than in OA patients. t-PA antigen levels were significantly lower in RA than in OA synovial tissue extracts. 
Immunohistochemistry was performed to compare the distribution and staining intensity of these components in samples of RA 
and OA synovial tissue. Intense immunostaining of u-PA, u-PAR, PAI-1 and, to a lesser degree, PAI-2 was observed 
predominantly in the synovial lining of RA patients. In OA patients, u-PA, PAI-1, PAI-2 and u-PAR were barely detectable. 
t-PA immunostaining was restricted to the endothelial side of vascular walls in both groups. We conclude that the observed 
increase o f u-PA, u-PAR and PAI expression, distributed mainly in the synovial lining area of proliferative and invasively 
growing synovia] tissue in RA patients, supports a pathogenic role for the PA system in destructive arthritis. Depressed 
t-PA-mediated plasminogen activation might contribute to delayed intra-articular fibrin removal.
K e y  w o rd s : Urokinase, Plasminogen activation, Immunohistochemistry, Rheumatoid arthritis. Osteoarthritis.
R h e u m a t o i d  arthritis (RA) is a chronic inflammatory 
disease, characterized by the destruction of articular 
cartilage and bone. Proteolytic degradation of the 
extracellular matrix in inflammatory arthritis is 
considered to be mediated by proteinases like aspartic, 
serine, cysteine and metalloproteinases [1], Hyper­
plastic inflamed synovial tissue overgrows and invades 
the articular cartilage, and may be involved in the 
destruction of bone, tendons and ligaments by the 
production of proteolytic enzymes [2, 3].
Several studies suggest an important pathogenic role 
of the plasminogen activation (PA) system in 
destructive joint disease [4-6], but detailed knowledge 
of the mechanism and components involved is lacking. 
The central enzyme, plasmin, is a broad-spectrum 
serine protease, involved in fibrinolysis and thrombo­
lysis as well as in the degradation of extracellular 
matrix that is required for normal and pathological 
forms of cellular invasiveness [7]. Plasmin is able to 
degrade extracellular matrix directly [8] and by 
activation of latent matrix metalloproteinases [9, 10]. It 
is produced as inactive plasminogen which is converted 
into its active form by limited proteolysis of a single 
peptide bond by plasminogen activators. Two types of 
plasminogen activators have been characterized: 
tissue-type plasminogen activator (t-PA), generally
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viewed as being important in fibrin dissolution, 
and urokinase-type plasminogen activator (u-PA), 
considered to be responsible for plasmin generation in 
processes involving tissue remodelling. Other identified 
proteins of the PA system include two plasminogen 
activator inhibitors, PAI-1 and PAI-2 [7], and a cell 
surface u-PA binding protein, the u-PA receptor 
(u-PAR). This receptor binds and localizes pro-u-PA as 
well as u-PA on the cell surface [11].
In patients with RA, a positive correlation between 
PA and PAI concentrations in synovial fluid and 
several markers of disease activity has been demon­
strated [12-14]. Increased levels of u-PA and PAI in 
synovial fluid of patients with inflammatory joint 
disease, compared with corresponding plasma levels, 
are indicative of local plasminogen activation [15]. 
Synovial fibroblasts, chondrocytes, and endothelial, 
mononuclear and polymorphonuclear cells are capable 
of synthesizing u-PA, t-PA, PAI-1 and PAI-2. These 
cells could be responsible for the local production of 
PA and PAI in RA [16-19]. It may be envisaged that
local plasminogen activation, in the proliferative and 
invasively growing synovial membrane, promotes the 
degradation of joint cartilage and bone.
In the present study, concentrations of several 
components of the PA system, i.e. u-PA, t-PA, PAI-1, 
PAI-2 and u-PAR, have been determined in extracts of 
synovial tissue of patients suffering from RA or OA 
requiring surgery. Furthermore, the distribution of 
these components has been investigated by immuno- 
histochemical staining of synovial tissue sections. In
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order to investigate a possible relationship between the 
level of synovial plasminogen activation and joint 
destruction, a comparison is made between the findings 
in destructive inflammatory arthritis, e.g. RA, with 
those in non-inliammatory, degenerative joint disease, 
i.e. OA. The results of this study support the 
pathogenic importance of the PA system in destructive 
joint disease.
MATERIALS AND METHODS
Tisane sampling and extraction 
Specimens of synovial tissue were obtained from 14 
RA patients and 12 OA patients who required joint 
surgery for severe disease. All RA patients, who 
fulfilled the established criteria [20], were operated on 
at the Orthopaedic Department 
Hospital, Leiden. Patients with 
corresponding to grade 3-4 in the 
classification [21], were operated
ire n
Department of Orthopaedics of Rijnland Hospital, 
Leiderdorp. Specimens of synovial tissue were immedi­
ately frozen in liquid nitrogen and stored at — 80‘ C 
until use.
For quantitative u-PA, t-PA, PAI-1, PAI-2 and 
u-PAR determination, tissue samples were homo­
genized in 1 ml 0.1% (v/v) Tween 80, 0.1 m  Tris-HCl 
buffer (pH 7.5) per 60 mg wet tissue, as described 
previously [22]. The homogenates were centrifuged 
twice at 8 x 103g for 2.5 min, and the supernatants 
collected and used in the assays. Protein concentrations 
were determined by the method of Lowry et al. [23].
'c assays
th
u-PA antigen was measured with an enzyme-linked 
immunoassay that was developed in our laboratory 
and performed according to Koolwijk et al. [24]. The 
monoclonal antibodies used in this ELISA recognize all 
forms of u-PA (pro u-PA, active u-PA and 
u-PA/PAI complex) with comparable efficiency. The 
detection limit is around 0.5 ng/ml. To assess u-PA 
activity, scu-PA and active tcu-PA were nieasur 
separately, using a biological immunoassay as 
described by Dooijewaard et al. [25].
t-PA antigen was determined using the commercial 
ELISA Imulyse t-PA (Biopool, Umea, Sweden). This
measures free t-PA antigen and t-PA/PAI 
complexes with the same sensitivity. The detection limit 
is ^ 1.5 ng/ml.
PAI-1 antigen was measured with Innotest PAI-1 
ELISA (Innogenetics, Antwerpen, Belgium), 
monoclonal mouse anti-human PAI-1 antibodies. This 
assay recognizes all forms of PAI-1 with the same 
sensitivity, with a detection limit of ~ 5  ng/ml. PAI-2 
antigen was measured with Tintelize PAI-2 ELISA 
(Biopool, Umea, Sweden), using monoclonal mouse 
anti-human PAI-2 antibodies. This assay recognizes all 
forms of PAI-2, including the low-molecular-weight 
form and the glycosylated high-molecular-weight form. 
The detection limit of this assay is — 6 ng/ml.
u-PAR antigen was measured with Imubind u-PAR 
ELISA (American Diagnostica Inc., Greenwich, CT,
TABLE l
Comparison of u-PA, t-PA, PAI-1, PAI-2 and u-PAR concentrations 
in synovial tissue o f  patients with rheumatoid arthritis (RA) and 
osteoarthritis (OA). Results are given as median and interquartile 
range (25-75%). The median concentrations o f  u-PA, PAI-1, PAI-2 
and u-PAR antigen in RA synovial tissue are significantly higher 
than those in OA synovial tissue. The median t-PA antigen 
concentration is significantly lower in RA than in OA synovial tissue
(Mann-Whitney [/-lest)
Parameter 
(ng/mg protein)
RA 
(n — 14)
OA 
(// 12) P
u-PA 6,9 (4.4 7.7) 0.03 (0 0.77) O.OOOl
t-PA 3.8 (3.0 6.1) 17 (10-28.8) 0.02
PAI-1 15.5 (6.5-30) 3.3 (2.4..5.5) 0.002
PA 1-2 0.1 (0 0.32) 0 ( 0 0 ) 0.01
u-PAR 2 (I.I 3.5) 0.8 (0.6 1.4) 0.01
USA), using polyclonal rabbit anti-human u-PAR. 
This assay recognizes soluble, native u-PAR as well
as u-PAR/u-PA and u-PAR/u-PA/PAI-1
The limit is 0.1 ng/ml.
immunoassays were performed in duplicate.
Antibodies
Monoclonal antibodies against human u-PA 
(#3698), polyclonal goat anti-human t-PA antibodies 
(#387), monoclonal anti-human PAI-1 (#380) and 
monoclonal anti-human u-PAR antibodies were
from American Diagnostica Inc.
ich, CT, USA). Goat polyclonal antibodies 
against human PAI-2 were a gift from E,
ring Werke AG, Marburg, Germany), 
characterization of these antibodies, including 
positive and negative controls, has been described in 
previous work [26, 37].
‘Iiemistrv
m
Tissue samples of five RA and five OA patients were 
frozen in isopentane and stored at — 80 'C. Cryostat 
sections (4 /¿m) were air ovenuK at room
a l »fii ■ilaii 80 C until use. Sections 
were fixed for 10 min in acetone at — 20’ C before 
incubation with the primary antibody.
is, a three-sten avidinWith
n  l u \ was
(Vectastain Elitekit, Vector Laboratories, Burlingame,
CA, as by Vries et 
to thePolyclonal antibodies were ap 
washed and incubated with peroxidase-labelled rabbit 
anti-goat immunoglobulin. Bound antibodies were
TABLE 11
ical expression o f  u-PA, t-PA, PA 1-1, PA 1-2 and 
u-PAR in synovial tissue of patients with rheumatoid arthritis (RA)
and osteoarthritis (OA)
u-PA
RA
O A
yc-jt«  ' " I
t-PA
4■ ■or
■1
I'
u-PAR
Ur \ f - l 4
g expression, 4- =  moderate expression, j 
no expression.
w ea k
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visualized by using 3-amino-9~ethylcarbazole as a 
substrate for peroxidase, as described previously [261.
Antigen concentrations were expressed as
nanograms of antigen per milligram of tissue protein. 
Differences between the median of the measured 
synovial tissue concentrations of u-PA, t-PA, PAI-1 
and PA 1-2 in the RA and the OA group were evaluated 
with the non-parametric Mann-Whitney U-test for
unpaired parameters, utilizing the standard software
‘Solo’ (BMDP Software, Los
Angeles, CA, USA). Differences were considered 
significant at P < 0.05.
RESULTS
Quantitative assays 
Enzyme-linked immunoassays were performed on 
homogenates of RA and OA synovial tissue samples to 
measure u-PA, t-PA, PAI-1, PAI-2 and u-PAR antigen
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F ig. 1. - Antigen concentration in synovial tissue samples of 14 patients with rheumatoid arthritis and 12 patients with osteoarthritis. Antigen 
was measured in tissue extracts by enzyme immunoassay and expressed as ng/mg tissue protein, (A) u-PA antigen; (B) t-PA antigen; (C) PAI-1 
antigen; (D) PAI-2 antigen; (E) u-PAR antigen. Statistical evaluation is summarized in Table I.
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levels. The results in RA patients were compared with 
those in OA patients.
u-PA antigen could be detected in all RA patients 
and in five out of 12 OA patients. When present, the 
u-PA concentration was considerably higher in RA 
than in OA synovial tissue samples (Fig. 1A). 
Statistical analysis revealed a significantly higher 
median value in RA compared with the median value 
in OA (Table I).
scu-PA and active tcu-PA were determined with a 
bioimmunoassay. The levels o f plasmin-activatable 
scu-PA and active tcu-PA in samples of synovial tissue 
of RA and OA patients were measured separately. 
Plasmin-activatable scu-PA could not be detected in 
synovial tissue from either RA  or OA patients, 
although active tcu-PA was found (data not shown).
t-PA levels were variable in both groups, but could 
be detected in all available samples (Fig. IB). In OA 
patient number 8, t-PA could not be measured because 
of a shortage of synovial tissue. The median 
concentration of t-PA antigen in the RA group was 
significantly lower than that in the OA group (Table I).
In all RA patients, and in 10 out of 12 OA patients, 
PAI-1 antigen was found in the synovial tissue 
(Fig. 1C). The median PAI-1 antigen level was 
significantly higher in the RA group than in the OA 
group (Table I).
PAI-2 related antigen was found in synovial tissue of 
eight out of 14 RA patients and could hardly be 
detected in one out of 12 OA tissue samples. PAI-2 
levels in RA synovial tissue were highly variable 
(Fig. ID). The difference between both groups 
appeared to be statistically significant (Table I).
In all samples of RA and OA patients, the presence 
of u-PAR antigen was detectable (Fig. IE). The median 
u-PAR level was significantly higher in the RA than in 
the OA group (Table I).
Immunohisto ch em is tr y
In order to investigate the localization of PA, PAI 
and u-PAR, immunohistochemistry was performed on 
sections of synovial tissue samples from live RA and 
five OA patients. The degree of expression of the 
various parameters is summarized in Table II and 
shown in Fig. 2. Marked expression of u-PA was seen 
in all RA synovial tissues, especially in the synovial 
lining cell area and in giant cells (Fig. 2A), but also in 
some plasma cells in inflammatory cell infiltrates. Less 
intense immunostaining was observed in some blood 
vessels, especially in the media of arterioles.
In the OA synovial tissue samples, hardly any u-PA 
could be detected (Fig. 2B), but when it was expressed, 
it was restricted to the synovial lining cell area.
t-PA was observed in the endothelial cells of 
capillaries in both groups (Fig. 2C and D). Modest 
expression was seen in the RA synovial lining area. No 
extravascular t-PA could be detected in OA synovial 
tissue.
Strong PAI-1 immunostaining was seen in all RA 
synovial tissue samples. It was confined to the lining 
cell area (Fig. 2E) and capillaries. Hardly any PAI-1
was observed in OA synovial tissue samples (Hg. 2K). 
In only a few RA patients, PAI-2 was observed in
parts of the synovial lining area (Fig. 2G). No PAI 
could be detected in any sample of OA patients
(Fig. 2H).
Substantial u-PAR expression, predominantly in 
lining cell area, was observed in synovial tissue of all
RA patients (Fig. 21). In OA synovial 
expression or only very weak expression of u- 
seen, mainly in association with 
the interstitium (Fig. 2J).
in
DISC
In the present study, we 
and localization of several
s of synovium obtained from patientsin s£
with RA and OA. As this enzyme 
be involved in extracellular proteolysis leading to joint 
destruction, a comparison is mt 
patient groups, to
between synovial tissue plasminogen 
joint destruction.
RA synovial tissue homogenates were 
contain variable but significantly higher concentrations 
of u-PA, PAI-1, PAI-2 and u-PAR than OA 
homogenates (Figs 1 and 2, Table I), 
histochemically, the picture was more homogeneous. 
u-PA, PAI and u-PAR appeared to be located mainly 
in the RA synovial lining. t-PA antigen levels in RA 
synovial tissue were lower than in OA synovial 
It was located predominantly in 
perivascularly.
The increase in u-PA, PAI-1, PAI-2 and u-PAR in 
tissue extracts of inflamed synovium presumably 
its origin in an enhanced local production. Increased 
levels of u-PA, PAI-1 
in synovial fluid of inflamed joints 
plasma [13-15] are indicative for generation
w i
m some severe cases 2Â x t
V*
the joint. Furthermore, m d
studies have demonstrated that synovial 
but
and endothelial 
u>PA and PAL In vivo 
influenced by cytokines s
are
necrosis -oc 2
stimulating factor [16
maerophuge co 1 ony
A local increase of u-PA at t £ 4 m
RA synovial tissue compared with OA synovial tissue 
is in line with previous observations in synovial 
[15] and in inflammatory bowel disease [27]. The altered
ratio of t-PA (high fibrin affinity) to u-PA (low 
affinity) could reflect a shift from 
degradation towards extracellular matrix degradation. 
This might result in protraction o f fibrin removal on
the one hand and enhanced proteolytic degradation of
other hand [15].joint bone and cartilage on 
The
histochemical analyses show a clear différence
data
RA and OA synovial tissue. T 
points towards an increased expression 
enzyme system components believed to be involved in
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tissue remodelling. A comparison between neoplastic 
tissue and invasively growing inflamed synovial tissue 
has been made before [7]. Indeed, increased u-PA and 
PAI-1 levels in tissue extracts or sections have been 
found in various malignant tumours [26, 28-30], and 
support the involvement of the PA system in 
extracellular matrix degradation, but how could an 
increased u-PA production lead to higher proteolytic 
activity when its inhibitors PAI-1 and PAI-2 are 
elevated? The answer may be found in the upregulation 
of u-PAR expression at the cell surface. First, in vitro 
studies have shown that several cell types are capable 
of binding u-PA at specific sites of the cell surface, 
whereas PAI was found at a different location [31]. 
Second, a differential inhibition of soluble and cell 
surface receptor-bound u-PA has been demonstrated 
[32], allowing enzymatic activity of receptor-bound
u-PA even in a PAI-rich environment. Third,
i '
co-localization of u-PA/u-PAR and plasminogen on
the cell surface results in 100-fold more efficient
activation of plasminogen than in the fluid phase [33], 
Furthermore, plasmin bound to the cell surface is 
resistant to a2-antiplasmin [34]. Fourth, the interaction 
of u-PA with its cell-bound receptor has been shown to 
strongly enhance the degradation of extracellular 
matrix [35]. Loss of the surface u-PA activity by 
blocking the interaction between the receptor and its 
ligand has been shown to inhibit invasive growth [36]. 
These phenomena could explain net local proteolytic 
activity in the presence of increased inhibitor. Our idea 
about the mechanism of plasmin-mediated joint 
destruction is that increased u-PA production by 
inflamed hypertrophic and hyperplastic synovial tissue, 
overgrowing cartilage in a ‘tumour-like’ manner, could 
lead to activation of the readily available plasminogen 
on the cell surface at sites occupied by u-PAR. 
This localized formation of active plasmin, capable 
of degrading extracellular matrix directly and by 
activation of matrix metalloproteinases, may sub­
sequently result in directed, proteolytic degradation of 
bone and cartilage.
In conclusion, the increased expression of u-PA, 
u-PAR, PAI-1 and PAI-2 in arthritic synovium 
compared with non-inflamed synovial tissue fits in with 
the concept of a localized, u-PA-mediated, plasmin- 
dependent degradation of articular structures, finding 
its origin in inflamed synovial tissue.
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